Empowered Patient Podcast AI-Powered Virtual Tumor Boards Democratize Access to Expert Cancer Analysis with Steve Brown and Lisa Booth CureWise
Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care. The platform also helps patients find relevant clinical trials and manage the side effects of their treatments.
Steve explains, "So the mission really is to harness AI to advance cancer care. And ultimately, for that reason, anybody who's touched by cancer is hopeful that we will be making more progress toward cures for cancer. And we believe that that's going to happen through precision medicine, which really means recognition that everybody's cancer is unique. And at some point, we're going to treat cancer that way because we're going to know enough about how it all works. We're going to be able to individualize care. So our mission is to advance that cause."
Lisa elaborates, "When Steve and I started working together, one of the things I said was that I needed a way as a patient to be able to access different perspectives of a radiologist, an interventional radiologist, a pathologist, a geneticist, an oncologist, etc. And I can get that in Seattle, but most of the people I work with can't, meaning the patients and my friends in the cancer community don't have access to that because they don't exist in their communities."
#CancerCare #AI #PrecisionMedicine #PatientEmpowerment #HealthTech #CancerSurvivors #DigitalHealth #Oncology #TumorBoard #ClinicalTrials #HealthcareInnovation #PatientAdvocacy #PatientLedInnovation #CancerAndAI #TumorBoardTech #AIForPatients #SteveBrownAI #LisaBoothSurvivor #MedicalAutonomy #HealthTechWithHeart #NOfOneMedicine